Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jan 24;17(1):72.
doi: 10.1186/s12885-017-3056-4.

Primary neuroendocrine breast carcinomas are associated with poor local control despite favourable biological profile: a retrospective clinical study

Nelli Roininen  1   2 , Sari Takala  3 , Kirsi-Maria Haapasaari  2 , Arja Jukkola-Vuorinen  1 , Johanna Mattson  3 , Päivi Heikkilä  4 , Peeter Karihtala  5
Affiliations

Primary neuroendocrine breast carcinomas are associated with poor local control despite favourable biological profile: a retrospective clinical study

Nelli Roininen et al. BMC Cancer. .

Abstract

Background: Breast carcinomas with neuroendocrine features (NEBC) are a very rare entity of mammary neoplasms, WHO classification of which has recently been revised. There are very limited data available about the clinical behaviour and treatment options of NEBC.

Methods: We collected retrospectively patients with NEBC from Oulu and Helsinki University Hospitals in 2007-2015. There were 43 NEBC cases during the period.

Results: The incidence of NEBC from all breast cancers varied from 0.1% in Helsinki to 1.3% in Oulu. The mean tumor size was 2.2 cm and 23 patients (55.8%) had no lymph node metastases when diagnosed. In total, 4 patients (9.3%) had distant metastases at the time of diagnosis. High estrogen receptor (ER) expression was observed in 41 (97.7%) patients. When non-metastatic NEBC were compared to a prospective set of ductal carcinomas (n = 506), NEBC were more often HER2 negative (p = 0.046), ER positive (p = 0.0062) and the NEBC patients were older (p < 0.0005) than patients with ductal carcinomas. Plasma chromogranin A correlated only to higher age at diagnosis (p = 0.0028). Relapse-free survival (p = 0.0013), disease-free survival (p = 0.024) and overall survival (p = 0.0028) favoured ductal carcinomas compared to NEBC, while no difference was observed in distant disease-free survival or in breast cancer-specific survival.

Conclusions: There is remarkable variation in the incidence of NEBC in Finland, which is likely to be explained by differences in the use of neuroendocrine marker immunostainings. Poor local control and worse overall survival may be linked to the more aggressive biology of the disease, despite its association with apparently indolent prognostic factors.

Keywords: Breast cancer; Incidence; Neuroendocrine carcinoma; Prognosis; World Health Organization.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Kaplan-Meier curves comparing neuroendocrine breast carcinomas and ductal breast carcinomas. Legend. Kaplan-Meier curves showing ipsilateral relapse-free survival (a), distant disease-free survival (b), disease-free survival (c), breast cancer-specific survival (d) and overall survival (e) in non-metastatic neuroendocrine breast carcinomas compared to a prospective set of local or locally advanced ductal breast carcinomas. Crosses indicate censored cases
See this image and copyright information in PMC

References

    1. Lakhani SR, Ellis I, Schnitt S. WHO classification of tumors of the breast. International agency for research on cancer. Lyon: IARC Press; 2012.
    1. López-Bonet E, Alonso-Ruano M, Barraza G, Vazquez-Martin A, Bernadó L, Menendez JA. Solid neuroendocrine breast carcinomas: incidence, clinico-pathological features and immunohistochemical profiling. Oncol Rep. 2008;20:1369–74. - PubMed
    1. Tavassoli FA, Devilee P. World Health Organization classification of tumors, pathology and genetics of tumors of the breast and female genital organs. Lyon: IARC Press; 2003.
    1. Adams RW, Dyson P, Barthelmes L. Neuroendocrine breast tumors: breast cancer or neuroendocrine cancer presenting in the breast? Breast. 2014;23:120–7. doi: 10.1016/j.breast.2013.11.005. - DOI - PubMed
    1. Miremadi A, Pinder SE, Lee AH, Bell JA, Paish EC, Wencyk P, et al. Neuroendocrine differentiation and prognosis in breast adenocarcinoma. Histopathology. 2002;40:215–20. doi: 10.1046/j.1365-2559.2002.01336.x. - DOI - PubMed

Publication types

MeSH terms